{{Rsnum
|rsid=403029
|Chromosome=10
|position=8090001
|Orientation=plus
|GMAF=0.2351
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 51.3 | 40.7 | 8.0
| HCB | 92.0 | 7.3 | 0.7
| JPT | 82.3 | 14.2 | 3.5
| YRI | 25.9 | 53.1 | 21.1
| ASW | 33.9 | 53.6 | 12.5
| CHB | 92.0 | 7.3 | 0.7
| CHD | 88.1 | 11.9 | 0.0
| GIH | 86.1 | 13.9 | 0.0
| LWK | 26.9 | 44.4 | 28.7
| MEX | 63.8 | 34.5 | 1.7
| MKK | 34.2 | 40.0 | 25.8
| TSI | 60.8 | 36.3 | 2.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs403029
|Name_s=
|Gene_s=GATA3
|Feature=NA
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109405
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs403029
|overall_frequency_n=82
|overall_frequency_d=124
|overall_frequency=0.66129
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}